MDMA meta-analysis stays positive; a psilocybin smoking cohort cut craving but not abstinence.
Pooling seven RCTs (published and unpublished, none retracted), MDMA-assisted therapy improved PTSD severity, dissociation, depression and functional impairment, but not sleep. In an observational smoking cohort, psilocybin-assisted care beat standard care on reduction and early urge scores while the adjusted abstinence odds ratio was 1.82 (95% CI 0.68-4.86).